ZA200900334B - DHA esters and use thereof in treatment and prevention of cardiovascular disease - Google Patents

DHA esters and use thereof in treatment and prevention of cardiovascular disease

Info

Publication number
ZA200900334B
ZA200900334B ZA2009/00334A ZA200900334A ZA200900334B ZA 200900334 B ZA200900334 B ZA 200900334B ZA 2009/00334 A ZA2009/00334 A ZA 2009/00334A ZA 200900334 A ZA200900334 A ZA 200900334A ZA 200900334 B ZA200900334 B ZA 200900334B
Authority
ZA
South Africa
Prior art keywords
prevention
treatment
cardiovascular disease
dha esters
dha
Prior art date
Application number
ZA2009/00334A
Other languages
English (en)
Inventor
Etienne Severac
Alain Marty
Jean Francois Patoiseau
Frederique Brune
Jean Gardette
Andre Delhon
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200900334(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA200900334B publication Critical patent/ZA200900334B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2009/00334A 2006-06-23 2009-01-15 DHA esters and use thereof in treatment and prevention of cardiovascular disease ZA200900334B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (en) 2006-06-23 2007-06-22 Dha esters and use thereof in treatment and prevention of cardiovascular disease

Publications (1)

Publication Number Publication Date
ZA200900334B true ZA200900334B (en) 2009-12-30

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/00334A ZA200900334B (en) 2006-06-23 2009-01-15 DHA esters and use thereof in treatment and prevention of cardiovascular disease

Country Status (38)

Country Link
US (2) US8034377B2 (https=)
EP (1) EP2034999B9 (https=)
JP (1) JP5053372B2 (https=)
KR (1) KR101380128B1 (https=)
CN (1) CN101472590A (https=)
AR (1) AR061622A1 (https=)
AT (1) ATE489091T1 (https=)
AU (1) AU2007262958B2 (https=)
BR (1) BRPI0713725A2 (https=)
CA (1) CA2655570C (https=)
CL (1) CL2010001123A1 (https=)
CO (1) CO6150156A2 (https=)
CR (1) CR10507A (https=)
DE (1) DE602007010776D1 (https=)
DK (1) DK2034999T3 (https=)
EC (1) ECSP099039A (https=)
ES (1) ES2355611T3 (https=)
FR (1) FR2902659A1 (https=)
GE (1) GEP20125464B (https=)
HN (1) HN2008001771A (https=)
HR (1) HRP20110086T1 (https=)
IL (1) IL195562A (https=)
MA (1) MA30584B1 (https=)
MX (1) MX2009000103A (https=)
MY (1) MY145985A (https=)
NO (1) NO20090334L (https=)
NZ (1) NZ573454A (https=)
PL (1) PL2034999T3 (https=)
PT (1) PT2034999E (https=)
RS (1) RS51629B (https=)
RU (1) RU2451672C2 (https=)
SA (1) SA07280345B1 (https=)
SI (1) SI2034999T1 (https=)
TN (1) TNSN08527A1 (https=)
TW (1) TWI389888B (https=)
UA (1) UA96156C2 (https=)
WO (1) WO2007147899A2 (https=)
ZA (1) ZA200900334B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
KR102167261B1 (ko) * 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
EP3582791A4 (en) * 2017-02-20 2021-03-31 The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College HYDROGEN SULPHIDE AND / OR NITRITE IN THE TREATMENT AND PREVENTION OF ATRIAL FIBRILLATION
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (https=) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
JPS59502024A (ja) 1982-11-16 1984-12-06 イレナ　モッチャン　マルス リュウマチ性疾病治療剤
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US6015821A (en) 1995-05-01 2000-01-18 Horrobin; David Frederick Nicotinic acid esters and pharmaceutical compositions containing them
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
CN1774179A (zh) 2003-04-17 2006-05-17 贝林格尔.英格海姆国际有限公司 供孕妇用的多种维生素及矿物质补充品

Also Published As

Publication number Publication date
EP2034999B1 (en) 2010-11-24
ATE489091T1 (de) 2010-12-15
EP2034999B9 (en) 2011-03-09
KR20090024794A (ko) 2009-03-09
RU2008152248A (ru) 2010-07-27
FR2902659A1 (fr) 2007-12-28
GEP20125464B (en) 2012-04-10
CL2010001123A1 (es) 2011-03-25
US8034377B2 (en) 2011-10-11
TNSN08527A1 (en) 2010-04-14
WO2007147899A3 (en) 2008-03-13
TWI389888B (zh) 2013-03-21
MX2009000103A (es) 2009-01-23
IL195562A (en) 2012-06-28
DK2034999T3 (da) 2011-01-24
PL2034999T3 (pl) 2011-05-31
BRPI0713725A2 (pt) 2012-10-30
AU2007262958B2 (en) 2011-10-27
WO2007147899A2 (en) 2007-12-27
ES2355611T3 (es) 2011-03-29
AR061622A1 (es) 2008-09-10
AU2007262958A1 (en) 2007-12-27
KR101380128B1 (ko) 2014-04-11
CA2655570A1 (en) 2007-12-27
IL195562A0 (en) 2009-09-01
US20090312354A1 (en) 2009-12-17
DE602007010776D1 (de) 2011-01-05
MY145985A (en) 2012-05-31
UA96156C2 (ru) 2011-10-10
HRP20110086T1 (hr) 2011-03-31
MA30584B1 (fr) 2009-07-01
CO6150156A2 (es) 2010-04-20
NO20090334L (no) 2009-03-04
TW200811108A (en) 2008-03-01
EP2034999A2 (en) 2009-03-18
JP2009544576A (ja) 2009-12-17
WO2007147899B1 (en) 2008-05-02
NZ573454A (en) 2010-10-29
CR10507A (es) 2009-02-05
SI2034999T1 (sl) 2011-02-28
US20110237613A1 (en) 2011-09-29
PT2034999E (pt) 2011-01-19
HN2008001771A (es) 2011-01-24
CA2655570C (en) 2015-09-08
JP5053372B2 (ja) 2012-10-17
US8227479B2 (en) 2012-07-24
ECSP099039A (es) 2009-02-27
RU2451672C2 (ru) 2012-05-27
CN101472590A (zh) 2009-07-01
RS51629B (sr) 2011-08-31
SA07280345B1 (ar) 2011-01-15

Similar Documents

Publication Publication Date Title
IL195562A0 (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
PT2546253E (pt) Di-hidropirazolonas substituídas para o tratamento de doenças cardiovasculares e hematológicas
EP1987065A4 (en) METHOD FOR IMPROVING THE IMMUNE FUNCTION AND METHOD FOR PREVENTING OR TREATING DISEASES IN MAMMALS
EP1919468A4 (en) TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
IL206080A (en) A pharmaceutical preparation for the treatment and / or prevention of bone and joint disease
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP1933880A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
WO2008106102A9 (en) Inhibitors of rtp801 and their use in disease treatment
PL2297106T3 (pl) Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
ZA200905273B (en) Compositions and methods of use of phorbol esters
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
PL2240193T3 (pl) Kompozycja zawierająca extrakty Lindera Obtusiloba do zapobiegania i leczenia chorób układu sercowo-naczyniowego
IL179931A0 (en) Compositions and methods for treatment of cardiovascular disease
EP2068861A4 (en) COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USE THEREOF IN THE TREATMENT OF PERIPHERAL ARTERIES DISEASE AND INTERMITTENT CLAUDICATION
IL197237A0 (en) Use of c7 sugars in prevention and treatment of mycoses
GB0608647D0 (en) Methods of diagnosis and treatment
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
ZA200807874B (en) Preventative treatment and remission of allergic diseases
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0602110D0 (en) Use of ultrasound in the diagnosis and treatment of multiple sclerosis
ZA200808072B (en) Heterocyclic compounds and their use in the treatment of cardiovascular disease